Home › Funds › Catalio Capital Management, LP › CRVS
Catalio Capital Management, LP position in CRVS
CORVUS PHARMACEUTICALS INC · Health Care
Catalio Capital Management, LP reported holding 1,021,499 shares of CRVS (CORVUS PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$11.8M, representing 2.20% of its reported portfolio and ranking #18 among its reported holdings. Catalio Capital Management, LP has disclosed CRVS holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Catalio Capital Management, LP's CRVS position evolved
Catalio Capital Management, LP first disclosed a stake in CRVS in Q1 2026 at 891,933 shares (US$13.0M). The position peaked in Q2 2026 at 1,080,888 shares, worth US$16.1M. Across 3 filings, Catalio Capital Management, LP increased the stake 1 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 1,021,499 shares valued at US$11.8M — a reduction of -59,389 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 891.93K | $13.05M | New |
| Q2 2026 | 1.08M | $16.15M | Add |
| Q3 2026 | 1.02M | $11.77M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About CRVS and 13F data
CRVS (CORVUS PHARMACEUTICALS INC) is a Health Care company. 54 other funds we track also report a position in CRVS — the largest reported positions include ORBIMED ADVISORS LLC (US$82.5M), ADAMS STREET PARTNERS LLC (US$37.7M), Vivo Capital, LLC (US$32.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding CRVS
- ORBIMED ADVISORS LLC 7.17M sh · $82.54M · Q3 2026
- ADAMS STREET PARTNERS LLC 3.28M sh · $37.74M · Q3 2026
- Vivo Capital, LLC 2.81M sh · $32.32M · Q3 2026
- PERCEPTIVE ADVISORS LLC 2.51M sh · $28.92M · Q3 2026
- Deep Track Capital, LP 2.49M sh · $28.71M · Q3 2026
- BRAIDWELL LP 1.93M sh · $22.25M · Q3 2026
- Foresite Capital Management VI LLC 1.83M sh · $21.10M · Q3 2026
- DCF Advisers, LLC 641.50K sh · $7.39M · Q3 2026
- Nextech Invest Ltd. 450.00K sh · $5.18M · Q3 2026
- Blue Owl Capital Holdings LP 358.60K sh · $4.13M · Q3 2026
- Propel Bio Management, LLC 264.31K sh · $3.04M · Q3 2026
- Spruce Street Capital LP 231.59K sh · $2.67M · Q3 2026
More on Catalio Capital Management, LP
FAQ
How long has Catalio Capital Management, LP held CRVS?
Catalio Capital Management, LP has disclosed CRVS holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
What is Catalio Capital Management, LP's current position in CRVS?
As of Q3 2026, Catalio Capital Management, LP holds 1.02M shares of CRVS (CORVUS PHARMACEUTICALS INC), valued at $11.77M, representing 2.20% of its reported portfolio and ranking #18.
Has Catalio Capital Management, LP been buying or selling CRVS?
In the latest 13F filing (Q3 2026), Catalio Capital Management, LP reduced its position in CRVS. The position peaked in Q2 2026 at 1.08M shares.
Which other funds hold CRVS?
Other major institutional holders of CRVS include ORBIMED ADVISORS LLC, ADAMS STREET PARTNERS LLC, Vivo Capital, LLC, among 54 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.